-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Although -X- _ O
several -X- _ O
therapeutic -X- _ O
options -X- _ O
have -X- _ O
become -X- _ O
available -X- _ O
for -X- _ O
patients -X- _ O
with -X- _ O
Cutaneous -X- _ O
T-cell -X- _ O
Lymphoma -X- _ O
( -X- _ O
CTCL -X- _ O
) -X- _ O
, -X- _ O
no -X- _ O
therapy -X- _ O
has -X- _ O
been -X- _ O
curative. -X- _ O
Recent -X- _ O
studies -X- _ O
have -X- _ O
demonstrated -X- _ O
that -X- _ O
CTCL -X- _ O
cells -X- _ O
overexpress -X- _ O
the -X- _ O
CC -X- _ O
chemokine -X- _ O
receptor -X- _ O
4 -X- _ O
( -X- _ O
CCR4 -X- _ O
) -X- _ O
. -X- _ O
METHODOLOGY -X- _ O
/ -X- _ O
PRINCIPAL -X- _ O
FINDINGS -X- _ O
: -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
a -X- _ O
xenograft -X- _ O
model -X- _ O
of -X- _ O
CTCL -X- _ O
was -X- _ O
established -X- _ O
and -X- _ O
a -X- _ O
recombinant -X- _ B-Intervention
adeno-associated -X- _ I-Intervention
viral -X- _ I-Intervention
serotype -X- _ I-Intervention
8 -X- _ I-Intervention
( -X- _ I-Intervention
AAV8 -X- _ I-Intervention
) -X- _ I-Intervention
vector -X- _ I-Intervention
expressing -X- _ I-Intervention
a -X- _ I-Intervention
humanized -X- _ I-Intervention
single-chain -X- _ I-Intervention
variable -X- _ I-Intervention
fragment -X- _ I-Intervention
( -X- _ I-Intervention
scFv -X- _ I-Intervention
) -X- _ I-Intervention
-Fc -X- _ I-Intervention
fusion -X- _ I-Intervention
( -X- _ I-Intervention
scFvFc -X- _ I-Intervention
or -X- _ I-Intervention
“minibody” -X- _ I-Intervention
) -X- _ I-Intervention
of -X- _ I-Intervention
anti-CCR4 -X- _ I-Intervention
monoclonal -X- _ I-Intervention
antibody -X- _ I-Intervention
( -X- _ I-Intervention
mAb -X- _ I-Intervention
) -X- _ I-Intervention
h1567 -X- _ I-Intervention
was -X- _ O
evaluated -X- _ O
for -X- _ O
curative -X- _ O
treatment. -X- _ O
Human -X- _ B-Patient
CCR4 -X- _ I-Patient
( -X- _ I-Patient
+ -X- _ I-Patient
) -X- _ I-Patient
tumor- -X- _ I-Patient
bearing -X- _ I-Patient
mice -X- _ I-Patient
treated -X- _ O
once -X- _ O
with -X- _ O
intravenous -X- _ O
infusion -X- _ O
of -X- _ O
AAV8 -X- _ B-Intervention
virions -X- _ I-Intervention
encoding -X- _ I-Intervention
the -X- _ I-Intervention
h1567 -X- _ I-Intervention
( -X- _ I-Intervention
AAV8- -X- _ I-Intervention
h1567 -X- _ I-Intervention
) -X- _ I-Intervention
minibody -X- _ I-Intervention
showed -X- _ B-Outcome
anti-tumor -X- _ I-Outcome
activity -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
and -X- _ I-Outcome
increased -X- _ I-Outcome
survival. -X- _ I-Outcome
The -X- _ O
AAV8-h1567 -X- _ B-Outcome
minibody -X- _ I-Outcome
notably -X- _ I-Outcome
increased -X- _ I-Outcome
the -X- _ I-Outcome
number -X- _ I-Outcome
of -X- _ I-Outcome
tumor-infiltrating -X- _ I-Outcome
Ly-6G -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
FcγRIIIa -X- _ I-Outcome
( -X- _ I-Outcome
CD16A -X- _ I-Outcome
) -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
murine -X- _ I-Outcome
neutrophils -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
tumor -X- _ I-Outcome
xenografts -X- _ I-Outcome
over -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
AAV8-control -X- _ I-Outcome
minibody -X- _ I-Outcome
treated -X- _ I-Outcome
mice. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
in -X- _ I-Outcome
CCR4 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
tumor-bearing -X- _ I-Outcome
mice -X- _ I-Outcome
co-treated -X- _ I-Outcome
with -X- _ I-Outcome
AAV8-h1567 -X- _ I-Outcome
minibody -X- _ I-Outcome
and -X- _ I-Outcome
infused -X- _ I-Outcome
with -X- _ I-Outcome
human -X- _ I-Outcome
peripheral -X- _ I-Outcome
blood -X- _ I-Outcome
mononuclear -X- _ I-Outcome
cells -X- _ I-Outcome
( -X- _ I-Outcome
PBMCs -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
marked -X- _ I-Outcome
tumor -X- _ I-Outcome
infiltration -X- _ I-Outcome
of -X- _ I-Outcome
human -X- _ I-Outcome
CD16A -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
CD56 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
NK -X- _ I-Outcome
cells -X- _ I-Outcome
was -X- _ I-Outcome
observed. -X- _ I-Outcome
The -X- _ O
h1567 -X- _ B-Outcome
minibody -X- _ I-Outcome
also -X- _ I-Outcome
induced -X- _ I-Outcome
in -X- _ I-Outcome
vitro -X- _ I-Outcome
ADCC -X- _ I-Outcome
activity -X- _ I-Outcome
through -X- _ I-Outcome
both -X- _ I-Outcome
mouse -X- _ I-Outcome
neutrophils -X- _ I-Outcome
and -X- _ I-Outcome
human -X- _ I-Outcome
NK -X- _ I-Outcome
cells. -X- _ I-Outcome
CONCLUSIONS -X- _ O
/ -X- _ O
SIGNIFICANCE -X- _ O
: -X- _ O
Overall -X- _ O
, -X- _ O
our -X- _ O
data -X- _ O
demonstrate -X- _ O
that -X- _ O
the -X- _ O
in -X- _ O
vivo -X- _ B-Outcome
anti-tumor -X- _ I-Outcome
activity -X- _ I-Outcome
of -X- _ I-Outcome
h1567 -X- _ I-Outcome
minibody -X- _ I-Outcome
is -X- _ I-Outcome
mediated -X- _ I-Outcome
, -X- _ I-Outcome
at -X- _ I-Outcome
least -X- _ I-Outcome
in -X- _ I-Outcome
part -X- _ I-Outcome
, -X- _ I-Outcome
through -X- _ I-Outcome
CD16A -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
immune -X- _ I-Outcome
effector -X- _ I-Outcome
cell -X- _ I-Outcome
ADCC -X- _ I-Outcome
mechanisms. -X- _ I-Outcome
These -X- _ O
data -X- _ O
further -X- _ O
demonstrate -X- _ O
the -X- _ O
utility -X- _ O
of -X- _ O
the -X- _ O
AAV-minibody -X- _ B-Intervention
gene -X- _ I-Intervention
transfer -X- _ I-Intervention
system -X- _ I-Intervention
in -X- _ O
the -X- _ O
rapid -X- _ O
evaluation -X- _ O
of -X- _ O
candidate -X- _ O
anti-tumor -X- _ O
mAbs -X- _ O
and -X- _ O
the -X- _ O
potency -X- _ O
of -X- _ O
h1567 -X- _ O
as -X- _ O
a -X- _ O
potential -X- _ O
novel -X- _ O
therapy -X- _ O
for -X- _ O
CTCL -X- _ O
. -X- _ O

